Hospira shareholders on Wednesday approved the $16 billion sale of the Chicago-area company to Pfizer, one of the world’s largest pharmaceutical companies.
Once the deal closes, Hospira shareholders will receive $90 a share in cash, a 39 percent premium to the closing price Feb. 4, the day before the transaction was announced.
At a special meeting of shareholders, 140.7 million votes were cast in favor of the deal, 326,868 votes against and there were 469,970 abstentions, according to a Hospira securities filing.
Hospira makes injectable drugs and infusion technologies. The company also is a leading player in the emerging market for lower-priced knockoffs of costly biotech drugs.
Pfizer has said it expects the deal to close in the second half of the year.